What is ABT's House Rating?

ABT scores 50 out of 100 (grade C) as of 2026-10-16, ranking #52 of 150 Health Care stocks we cover.

What do analysts say about ABT?

ThetaGrade's analyst-sentiment pillar for ABT scores 83/100 against its sector peers, which we read as positive. This is our own derived score; we do not republish individual analyst ratings, counts or targets.

When does ABT report earnings next?

ABT has announced its next earnings report for 2026-10-21 (source: Abbott press release, Sep 30, 2026).

ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.

ABT Abbott Laboratories

Health Care · Health Care Equipment · close $104.89 (2026-10-16) · latest quarter in EDGAR: 2026-03-31

#52/150 in sector · #399/964 overall

Abbott Laboratories (ABT) has a ThetaGrade House Rating of 50/100 (grade C), ranking #52 of 150 in Health Care. Its strongest pillars are analyst sentiment (83) and cash flow (63); its weakest is balance sheet (35). TTM revenue growth is 6.6% and operating margin 17.1%.

Data as of 2026-10-16.

Analyst sentiment

weight 7.5% · 83

Consensus score (1–5) (3.8%)	derived	83
90-day net rating shift (3.8%)	derived	70

Growth

weight 30.83% · 35

Revenue growth YoY (TTM) (12.3%)	6.6%	33
EPS growth YoY (TTM) (12.3%)	-53.6%	17
Revenue acceleration (6.2%)	3.4%	76

Profitability

weight 18.5% · 62

Operating margin (9.9%)	17.1%	63
4Q gross-margin change (8.6%)	0.4%	61

Balance sheet

weight 18.5% · 35

Net debt / EBITDA (9.9%)	2.98×	25
Current ratio (4.9%)	1.39	23
Interest coverage (3.7%)	15.63×	78

Cash flow

weight 12.33% · 63

FCF margin (6.2%)	16.7%	63
FCF yield (6.2%)	4.0%	64

Valuation

weight 12.33% · 55

P/E (inverted) (6.2%)	29.38×	54
EV/Sales (inverted) (6.2%)	4.65×	55

Technicals (EOD)

RSI(14)	59.0
EMA 9 / 21	102.29 / 102.04 · crossed up 1d ago
200-day SMA	102.81
Volume vs 20d avg	0.84×
20-day return	2.6%

Exit-rule monitor

EXITRating break: House Rating below 60

Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: Revenue − CostOfGoodsAndServicesSold · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: Depreciation · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).

Get rating changes like ABT's in the free Daily Brief

The market’s key events and signals, digested before the open.

✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
✓ OPEX, FOMC, CPI and jobs-day reminders

Free. Want more? See Premium (waitlist).

FAQ

What is ABT's House Rating?: ABT scores 50 out of 100 (grade C) as of 2026-10-16, ranking #52 of 150 Health Care stocks we cover.
What do analysts say about ABT?: ThetaGrade's analyst-sentiment pillar for ABT scores 83/100 against its sector peers, which we read as positive. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
When does ABT report earnings next?: ABT has announced its next earnings report for 2026-10-21 (source: Abbott press release, Sep 30, 2026).
Is ABT a buy?: ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.

Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology